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The epidemiology of symptomatic midfoot
osteoarthritis in community-dwelling older
adults: cross-sectional findings from the
Clinical Assessment Study of the Foot
Martin J. Thomas1*, George Peat1, Trishna Rathod1, Michelle Marshall1, Andrew Moore2, Hylton B. Menz1,3
and Edward Roddy1
Abstract
Introduction: The foot is largely overlooked in calls for better characterisation of clinical phenotypes in osteoarthritis
(OA). Yet the midfoot complex in particular has the potential to provide important insights into OA pathogenesis given
its central role in lower limb load transmission and alignment. Its recent inclusion in radiographic atlases has paved the
way for international studies. In this UK study, we provide the first comprehensive account of the descriptive
epidemiology of symptomatic midfoot OA.
Methods: Participants aged ≥50 years registered with four general practices were recruited via a mailed health survey
(n = 5109 responders) and research clinic (n = 560 responders). Symptomatic midfoot OA was defined as midfoot pain
in the last 4 weeks, combined with radiographic OA in one or more joints (1st and 2nd cuneometatarsal, navicular first
cuneiform and talonavicular joints) graded from weight-bearing dorso-plantar and lateral radiographs using a validated
atlas. Prevalence estimates, overall and stratified by age, gender, and socio-economic class, were derived using multiple
imputation and weighted logistic regression. Associations between symptomatic midfoot OA and current body mass
index, previous injury, history of high-heeled footwear, nodal interphalangeal joint OA and patterns of comorbidity
were estimated using binary logistic regression. Healthcare use was summarised.
Results: Symptomatic midfoot OA was present in 12.0 % (95 % CI: 10.9, 13.2) of the population aged over 50 years.
Higher occurrence was observed in females, adults aged over 75 years, and those in intermediate/routine occupational
classes. Obesity, previous foot/ankle injury, and pain in other weight-loaded joints, but not high-heeled footwear or
nodal interphalangeal joint OA, were associated with increased risk of symptomatic midfoot OA. Persons with
symptomatic midfoot OA were also more likely to report multiple non-musculoskeletal comorbidities, including
diabetes. In the previous 12 months, the proportions consulting a general practitioner, physiotherapist or
podiatrist/chiropodist about foot pain were 46.2 %, 18.5 % and 47.9 % respectively. A total of 64.7 % had used oral
analgesia in the past month for foot pain (36.1 % paracetamol, 31.9 % mild/moderate opioids, 27.7 % NSAIDs).
Conclusions: Our study confirms that symptomatic OA frequently affects the midfoot. The patterns of associations
are interpreted as being largely consistent with the role of mechanical factors in its pathogenesis.
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Introduction
Symptomatic osteoarthritis (OA) is now widely accepted
as being a multifactorial pathology affecting the whole
joint complex [1]. The different aetiology, risk factors
and prognosis seen across different joint sites, such as
the hip, knee and hand, suggest that characterisation of
discrete clinically relevant OA phenotypes is necessary
to enable targeted treatment interventions to be devel-
oped [2].
Although the foot has largely been neglected relative
to other sites commonly affected by OA [3], persistent
foot pain is common in older adults [4], with approxi-
mately one in six estimated to have symptomatic foot
OA [5]. As with other regions of the body, OA of the
foot joint complex may comprise more than one pheno-
type. Recent latent class analysis of radiographic foot OA
at five key sites (1st metatarsophalangeal joint (MTPJ), 1st
and 2nd cuneometatarsal joint (CMJs), navicular first
cuneiform joint (NCJ) and talonavicular joint (TNJ)) iden-
tified an isolated bilateral 1st MTPJ OA group and a poly-
articular midfoot-dominant OA group as possible distinct
radiographic phenotypes [6]. In the foot, the predominant
focus of epidemiological studies has been on OA at the
1st MTPJ [3]. However, better characterisation of a symp-
tomatic midfoot OA phenotype could facilitate more tar-
geted clinical assessment and management, particularly as
primary care diagnosis of foot symptoms is often limited
and unclear [7, 8].
The midfoot also presents a particularly interesting
complex in which to investigate OA given its important
load distribution function [9], enabling the foot to con-
form to terrain and yet provide a rigid lever for forward
motion when walking. It remains highly speculative
whether OA in the midfoot has important implications
for the development of OA in adjacent joints. Case
series reporting high rates of OA in adjacent joints
following midfoot fusion (for example, [10, 11]) have
lacked appropriate control observations and may be con-
founded by factors associated with both midfoot fusion
and OA in other foot joints.
The objectives of this study were to: (i) provide
population prevalence estimates for symptomatic mid-
foot OA (including estimates for midfoot pain and dis-
abling symptomatic midfoot OA) in adults aged 50 years
and over, (ii) examine the association with selected po-
tential aetiological factors, (iii) describe associated pat-
terns of comorbidity, and (iv) determine the frequency
of selected healthcare use for foot pain among persons
with symptomatic midfoot OA.
Methods
Study design
This paper utilises baseline data from a population-
based prospective observational cohort study, the Clinical
Assessment Study of the Foot (CASF) [12]. Adults aged
50 years and over registered with four general practices in
North Staffordshire, United Kingdom, were invited to take
part in the study, irrespective of foot-related consult-
ation. Ethical approval was obtained from Coventry
Research Ethics Committee (REC reference number: 10/
H1210/5) and all participants gave their written consent
to participate.
Data collection
At baseline, eligible participants were mailed a health
survey that included general health (Short Form-12 (SF-
12)) [13], Hospital Anxiety and Depression Scale (HADS)
[14], comorbidities, anthropometric characteristics (self-
reported height and weight), foot pain, footwear, health-
care consultation, pain medication use, and demographic
and socio-economic characteristics (age, gender, marital
status, education, current employment status, and occupa-
tion). Foot pain questions included: pain in the foot in the
last 12 months; pain, aching or stiffness in the foot in the
last month [15], number of days with foot pain in the last
12 months; and the Manchester Foot Pain and Disability
Index (MFPDI) [16]. The location of foot pain in the last
4 weeks was ascertained from shading a foot manikin
(© The University of Manchester 2000. All rights re-
served) [17]. Participants who reported foot pain in the
last 12 months and provided written consent to further
contact were invited to attend a research assessment clinic
where weight-bearing dorso-plantar and lateral radio-
graphs of each foot, clinical interview and physical exam-
ination were undertaken, in accordance with defined
standardised protocols [12, 18]. Health survey responders
were also invited to consent to medical record review.
Scoring of radiographs and case definitions
Plain radiographs were scored by a single reader (MM)
blinded to all other participant information. Osteophytes
and joint space narrowing at the 1st and 2nd CMJs, NCJ
and TNJ were scored (0–3) according to a validated atlas
and classification system [18]. Eight weeks later a ran-
dom selection of radiographs from 60 participants were
re-scored by MM and independently by HBM. Intra-
rater and inter-rater reliability for the presence of OA in
a midfoot joint were excellent (mean κ = 0.95, mean %
agreement = 99 %) and moderate (mean κ = 0.40, mean %
agreement = 78 %) respectively.
Midfoot pain was defined as self-reported pain in the
last 4 weeks by shading the midfoot region on a foot
manikin, designated using a pre-defined regional mark-
ing template [17, 19].
Symptomatic midfoot OA was defined as a radio-
graphic score of 2 or more for osteophytes or joint space
narrowing on either weight-bearing dorso-plantar or lat-
eral views, in one or more midfoot joints (1st CMJ, 2nd
Thomas et al. Arthritis Research & Therapy  (2015) 17:178 Page 2 of 11
CMJ, NCJ or TNJ), and midfoot pain in the last 4 weeks
in the same foot (as defined above).
Disabling symptomatic midfoot OA was defined as
symptomatic radiographic OA together with at least one
of the ten items within the MFPDI function construct
scored at the level of ‘on most/every day(s)’ [20]. If all
items were scored at the level of ‘none of the time’ or ‘on
some days’, symptomatic midfoot OA was classed as non-
disabling. Individuals were defined as having any of the
above case definitions if either or both feet were affected.
Individuals identified as having non-specific inflamma-
tory arthritis, rheumatoid arthritis, or psoriatic arthritis
were excluded from the analyses based on medical record
review (primary care and local hospital) or clinical X-ray
report by a consultant musculoskeletal radiologist [5].
Statistical analysis
Estimating population prevalence
Using baseline health survey and radiographic data, the
population prevalence of midfoot pain, symptomatic
midfoot OA and disabling symptomatic midfoot OA in
the individual were estimated using multiple imputation
and weighted logistic regression modelling. Multiple im-
putation was used to account for missing item-level data
from the health survey and estimates were then weighted
to take into account selective non-response to the health
survey [21]. Missing data were inspected to ensure that
the missing at random assumption was reasonable.
Imputation involved all baseline responders and uti-
lised the following variables: age, gender, general prac-
tice, social class, marital status, number of days with
foot pain in the last 12 months, Rasch-transformed
MFPDI interval level scores for the pain and function
constructs [22], individual MFPDI function items to esti-
mate disabling symptoms [20], self-reported foot pain,
aching, or stiffness in the last month, SF-12 score, HADS
score, and radiographic foot OA and pain regions. Fifteen
imputed datasets were generated and combined using
Rubin’s combination rules [23]. Prevalence estimates (and
95 % confidence intervals (CI)) were calculated using the
mim: proportion command and applied to the total base-
line responder population. Selective non-response to the
health survey was handled by generating weighted esti-
mates that likely reflect the profile of non-responders
using information available for the whole eligible baseline
population (age, gender and general practice). Weighted
logistic regression was combined with the imputed data-
sets to generate prevalence estimates (and 95 % CI) in the
whole eligible baseline population. Crude population
prevalence estimates for midfoot pain, symptomatic
radiographic midfoot OA and disabling radiographic
symptomatic midfoot OA were then stratified by gender,
age, and socio-economic class, based on occupation.
This approach to estimating population prevalence
mirrors our procedures adopted for estimating overall
symptomatic radiographic foot OA [5].
The analyses described below were conducted using
data from the CASF clinic cohort. A complete case ap-
proach was taken due to the generally very low levels of
missing data within clinic participants.
Potential aetiological determinants of interest
Binary logistic regression estimated the crude, and as ap-
propriate, age-gender-body mass index (BMI)-adjusted
associations between symptomatic midfoot OA and se-
lected variables. Obesity (≥30 kg/m2) at time of baseline
assessment was calculated from clinic-measured height
and weight. Lifetime recall of previous foot and ankle in-
jury was ascertained on standardised personal interview
(yes/no response to the question ‘Have you ever injured
your feet or ankles?’, with follow-up questions to ascer-
tain type, anatomical location and duration of time since
injury, analysed in right feet only). Lifetime recall of fre-
quent use of high-heeled footwear among females was
ascertained from a health survey item on footwear [12]
(high frequency use was defined as reported use of high-
heeled shoes on most days for at least one 10-year
period between the age of 20 and 49 years). Nodal inter-
phalangeal joint (IPJ) OA was defined as a Kellgren and
Lawrence [24] score of two or more, in two or more IPJs
(digits 2–5) and the presence of two or more Heberden
or Bouchard nodes (digits 2–5) across either hand [25].
Associated impairment and comorbidities
The following self-reported impairment and comorbidi-
ties were ascertained from the health survey and their
associations with symptomatic midfoot OA examined
using binary logistic regression: general health and
function (SF-12 physical and mental components, with
each variable dichotomised around the median of the
data distribution), HADS score (categorised as normal,
mild, moderate or severe), chest problems, heart prob-
lems, deafness, eyesight problems, hypertension, dia-
betes, stroke, cancer, circulation problems in the legs,
intermittent claudication (defined by the Edinburgh
Claudication Questionnaire [26]) and co-occurring joint
pain in the last month at other weight-loaded sites (low
back, hip, knee, hindfoot/ankle and forefoot). Pain loca-
tion was defined using recognised body and foot mani-
kins and templates (low back [27]; hip [28]; knee [29];
foot and ankle [17]) that have demonstrated excellent
inter- and intra-rater reliability [19, 29]. Crude odds ra-
tios (OR) with 95 % CI were reported together with esti-
mates adjusted for age and gender.
Frequency of primary healthcare use
Among adults with symptomatic midfoot OA, the fre-
quency of foot pain-related consultation with a general
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practitioner (GP) or allied health professional (physio-
therapist or podiatrist/chiropodist) was summarised as
the 12-month period prevalence, and the proportion of
consultations that were with the National Health Service
(NHS) or private practice was described. The frequency
of medication use for foot pain among adults with symp-
tomatic midfoot OA was summarised as 1-month period
prevalence.
All analyses were conducted using STATA V.12.0
(StataCorp, College Station, TX, USA).
Results
The description of participants recruited into the study has
been previously reported [5]. Briefly, in 2010/2011, 9403
potentially eligible adults were identified. Following initial
screening, 9194 were posted a health survey, with 5109
responding (adjusted response 56 %). Following further
screening, 1634 eligible participants were invited to a
research clinic, 560 (34 %) of whom attended. In total,
525 contributed to the final analyses following the exclu-
sion of those with incomplete foot pain data (n = 8),
incomplete radiographic data (n = 3) and inflammatory
arthritis (n = 24).
Population prevalence
The population prevalence of midfoot pain in the last
month among adults aged 50 years and over was 19.4 %
(95 % CI: 18.3 %, 20.5 %). The corresponding estimate
for symptomatic midfoot OA was 12.0 % (95 % CI: 10.9 %,
13.2 %) and for disabling symptomatic midfoot OA was
9.6 % (95 % CI: 8.6 %, 10.6 %). Based on the imputed esti-
mates, a prevalence staircase was constructed for a denom-
inator population of 10, 000 persons aged 50 years and
over (Fig. 1). Prevalence was higher in females, increased
most notably in females aged 75 years and over, and was
inversely related to socio-economic class (Table 1).
Among clinic attenders, 149 individual feet were diag-
nosed with symptomatic midfoot OA. Of these, most
feet (n = 100, 67 %) had only one joint involved, with the
2nd CMJ being most commonly affected (n = 39, 39 %),
followed by the TNJ (n = 36, 36 %), 1st CMJ (n = 13,
13 %) then NCJ (n = 12, 12 %).
Potential aetiological determinants of interest
Symptomatic midfoot OA was positively associated with
BMI. However, for self-reported previous foot or ankle
injury, previous frequent use of high-heeled footwear
among females and nodal IPJ OA, the 95 % CI for these
estimates crossed unity (Table 2). Further analyses of
previous foot or ankle injury among right feet suggested
that those with symptomatic midfoot OA were more
likely to recall having a fracture (Table 3). Examining all
foot and ankle injuries to the right foot (n = 42, with 49
injuries), the ankle was reported as the most commonly
affected location, particularly for a sprain (41 %), and
this was followed by forefoot fracture (16 %) and other
forefoot injuries (14 %). Additionally, most recalled in-
juries occurred over 10 years prior to baseline clinic as-
sessment (56 %) (Table S1 in Additional file 1).
Associated impairment and comorbidities
Strong positive associations were observed between
symptomatic midfoot OA and impaired physical func-
tion measured by the SF-12, mild and moderate anxiety
and mild depression measured using the HADS scores,
and diabetes. Following further adjustment for BMI, the
positive association with diabetes was attenuated (OR,
1.48; 95 %CI: 0.85, 2.55). Observed associations between
symptomatic midfoot OA and four or more comorbidi-
ties, and self-reported pain at all weight-loaded joint
sites of the body were positive. For co-occurring joint
pain, increased magnitude but reduced precision was ob-
served for sites closest to the midfoot (hindfoot/ankle
and forefoot) (Table 4). The observed positive associa-
tions across all the weight-loaded joint sites remained
following further adjustment for BMI (data not shown).
Frequency of primary healthcare use
Most participants with symptomatic midfoot OA con-
sulted a healthcare professional in the last 12 months
for foot pain, with the frequency of GP and podiatrist/
chiropodist consultations being similar (Table 5). Among
individuals with symptomatic midfoot OA in either foot
(n = 119), 16 % had accessed private allied health profes-
sional healthcare for foot pain in the last 12 months
Fig. 1 Prevalence staircase for symptomatic midfoot OA
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(22 %, n = 5 of physiotherapy consultations, and 25 %,
n = 14 of podiatry/chiropody consultations).
One-month period prevalence of pain medication use
for foot pain was 70.6 % (95 % CI: 62.3, 78.9) (Table 5).
One-month period prevalence for one or more form of
oral pain medication use (paracetamol, non-steroidal anti-
inflammatory drugs, including coxibs and mild/moderate
opioids) was 64.7 % (95 % CI: 55.9, 73.4). Pain medication
and topical applications were more frequently used than
herbal/nutraceutical preparations.
Discussion
This is the first comprehensive account describing the
epidemiology of symptomatic midfoot OA. Our find-
ings suggest that symptomatic midfoot OA is common,
being present in an estimated 12 % of the population
aged 50 years and over. The higher occurrence of
symptomatic midfoot OA in females, older age, and
lower socio-economic classes is consistent with previ-
ous epidemiological studies of foot pain and other sites
of musculoskeletal pain [4, 30].
The associations with obesity, previous injury and pain
at all other weight-loaded joint sites but not nodal IPJ
OA (a proxy for more widespread OA [31]), together with
the load distribution function of the midfoot [9], are
consistent with the role of mechanical factors in its patho-
genesis. Whilst no one underlying mechanism (e.g. inflam-
matory or mechanical) appears to be responsible in its
entirety for the development of OA [32, 33], the charac-
teristics of deterioration associated with structural and
pathological changes suggest that altered biomechanics
and joint loading are important modifiable mediators of
onset and progression, particularly in the lower limb [34].
At the knee, epidemiological studies have shown malalign-
ment and aberrant loading to be associated with OA
development (for example, [35, 36]). As a functional unit,
the midfoot is highly sensitive to aberrant biomechanics
and altered joint loading due to its load distribution
function when walking [37, 38], and our epidemiological
findings provide additional evidence in support of a mala-
lignment loading hypothesis. Within the midfoot joints
imaged and scored, isolated midfoot joint involvement
was the predominant observation, with the 2nd CMJ be-
ing the most frequently affected joint, followed by the
TNJ. The mechanical vulnerability of the 2nd CMJ as the
more rigid apex of the transverse arch [39] appears con-
sistent with a greater susceptibility to aberrant loading
compared with the TNJ, which structurally has more
Table 1 Population prevalence of midfoot pain, symptomatic, and disabling symptomatic midfoot OA by demographic
characteristics
Midfoot pain Symptomatic midfoot OA Disabling symptomatic midfoot OA
All adults aged 50+ 19.4 (18.3, 20.5) 12.0 (10.9, 13.2) 9.6 (8.6, 10.6)
Gender
Male 17.2 (15.7, 18.7) 10.3 (8.9, 11.7) 7.9 (6.7, 9.1)
Female 21.5 (19.9, 23.1) 13.7 (12.0, 15.5) 11.2 (9.7, 12.8)
Age (years) overall
50–64 20.6 (19.0, 22.2) 11.8 (10.0, 13.5) 9.0 (7.5, 10.4)
65–74 17.6 (15.7, 19.5) 11.1 (9.4, 12.8) 8.8 (7.2, 10.4)
75+ 18.7 (16.3, 21.1) 14.4 (11.9, 16.9) 13.0 (10.7, 15.3)
Males
50–64 18.8 (16.6, 21.0) 10.5 (8.4, 12.6) 7.5 (5.9, 9.1)
65–74 15.1 (12.5, 17.6) 9.3 (6.9, 11.7) 7.8 (5.5, 10.0)
75+ 15.4 (11.8, 18.9) 11.3 (8.0, 14.6) 9.9 (6.8, 12.3)
Females
50–64 22.4 (20.1, 24.7) 13.1 (10.6, 15.5) 10.5 (8.3, 12.6)
65–74 20.2 (17.3, 23.1) 12.9 (10.1, 15.8) 9.9 (7.4, 12.4)
75+ 21.1 (17.8, 24.4) 16.6 (13.2, 20.0) 15.3 (12.1, 18.5)
Socio-economic classification
Managerial and professional 12.7 (10.6, 14.7) 6.9 (4.9, 8.9) 4.9 (3.3, 6.5)
Intermediate occupations 18.8 (16.2, 21.4) 12.6 (9.9, 15.4) 10.5 (8.2, 12.8)
Routine and manual 21.6 (20.0, 23.2) 13.3 (11.6, 15.0) 10.5 (9.1, 11.9)
Based on imputed and weighted analyses
OA osteoarthritis
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functional capacity to accommodate larger gravitational
loading effects, together with shear forces during both
static and dynamic functional tasks. Different patterns of
single joint involvement may reflect different midfoot
loading patterns. Although the observed positive associa-
tions between symptomatic midfoot OA and obesity ex-
tend earlier work, showing that being obese is associated
with non-specific foot pain [40], further research is re-
quired to confirm or refute a more systemic counterargu-
ment for the involvement of obesity [41].
The observed trend that previous injury is associated
with symptomatic midfoot OA supports expert clinical
opinion that OA changes in the midfoot commonly fol-
low trauma [42] and mirrors a well-established associ-
ation between injury and OA in the knee [43]. However,
more research is needed to better understand the rela-
tionships between symptomatic midfoot OA and transi-
ent minor traumas versus chronic injury mechanisms
and consequences. Whilst footwear selection for females
may also precipitate a range of foot-related problems
Table 3 Associations between right symptomatic midfoot OA and previous right foot or ankle injury
Self-reported right foot or ankle injury Total N RSMOA N Crude OR (95 % CI) Adjusted OR (95 % CI)a
One or more previous injury
No 269 37 1 1
Yes 256 42 1.23 (0.76, 1.99) 1.30 (0.79, 2.12)
One or more previous sprain
No 342 56 1 1
Yes 167 21 0.73 (0.43, 1.26) 0.80 (0.46, 1.39)
One or more previous fracture
No 433 59 1 1
Yes 83 20 2.01 (1.13, 3.57) 2.06 (1.14, 3.71)
One or more previous other injury
No 443 65 1 1
Yes 72 12 1.16 (0.59, 2.28) 1.08 (0.54, 2.15)
Based on complete case clinic data
OA osteoarthritis, RSMOA right symptomatic midfoot osteoarthritis, OR odds ratio, CI confidence interval
aEstimates adjusted for age, gender and body mass index
Table 2 Relationship between selected potential aetiological determinants of interest and symptomatic midfoot OA
Total N SMOA N Crude OR (95 % CI) Adjusted OR (95 % CI)
Body mass index (kg/m2)
Non-obese <30 286 49 1 1
Obese ≥30 235 69 2.01 (1.33, 3.05) 2.02 (1.32, 3.08)a
Self-reported previous injury to either foot or ankle
No 166 29 1 1
Yes 359 90 1.58 (0.99, 2.52) 1.60 (0.98, 2.60)b
Self-reported frequency of use of high-heeled footwearc
Low 78 18 1 1
High 211 47 0.96 (0.51, 1.77) 0.98 (0.51, 1.88)d
Nodal IPJ OAe
No 402 85 1 1
Yes 123 34 1.42 (0.90, 2.26) 1.32 (0.80, 2.16)b
Based on complete case clinic data
OA osteoarthritis, SMOA symptomatic midfoot osteoarthritis, OR odds ratio, CI confidence interval, IPJ interphalangeal joint
aEstimate adjusted for age and gender
bEstimate adjusted for age, gender and body mass index
cExamination was restricted to females and the exposure was defined as previous footwear (low- versus high-heeled shoes) worn on most days for at least one
10-year period between 20 and 49 years old
dEstimate adjusted for age and body mass index
eNodal interphalangeal joint (IPJ) OA defined as Kellgren and Lawrence ≥2 in ≥2 IPJs (digits 2–5), and the presence of ≥2 Heberden or Bouchard nodes
(digits 2–5) across either hand [25]
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Table 4 Associated self-reported impairment and comorbidities among adults with symptomatic midfoot OA
Self-reported impairment/comorbidity Total N SMOA N Crude OR (95 % CI) Adjusted ORa (95 % CI)
SF-12 Physical impairmentb
No 242 30 1 1
Yes 245 76 3.18 (1.99, 5.08) 2.87 (1.78, 4.62)
SF-12 Mental impairmentb
No 240 45 1 1
Yes 247 61 1.42 (0.92, 2.19) 1.42 (0.91, 2.21)
HADS anxiety
Normal (0–7) 289 52 1 1
Mild (8–10) 114 30 1.63 (0.97, 2.72) 1.73 (1.02, 2.94)
Moderate (11–14) 92 29 2.10 (1.23, 3.57) 2.26 (1.30, 3.93)
Severe (15–21) 23 6 1.61 (0.60, 4.28) 1.99 (0.74, 5.39)
HADS depression
Normal (0–7) 371 71 1 1
Mild (8–10) 86 27 1.93 (1.15, 3.26) 1.86 (1.09, 3.17)
Moderate (11–14) 50 16 1.99 (1.04, 3.80) 1.93 (0.99, 3.75)
Severe (15–21) 11 3 1.58 (0.41, 6.12) 2.11 (0.54, 8.28)
Chest problems
No 411 87 1 1
Yes 114 32 1.45 (0.91, 2.33) 1.34 (0.83, 2.18)
Heart problems
No 424 88 1 1
Yes 101 31 1.69 (1.04, 2.74) 1.48 (0.90, 2.43)
Deafness
No 401 89 1 1
Yes 124 30 1.12 (0.70, 1.80) 0.90 (0.55, 1.49)
Eyesight problemsc
No 381 82 1 1
Yes 144 37 1.26 (0.81, 1.97) 1.13 (0.71, 1.78)
Hypertension
No 284 53 1 1
Yes 241 66 1.64 (1.09, 2.48) 1.40, (0.92, 2.15)
Diabetes
No 444 90 1 1
Yes 81 29 2.19 (1.32, 3.65) 1.93 (1.14, 3.25)
Stroke
No 492 113 1 1
Yes 33 6 0.75 (0.30, 1.85) 0.59 (0.23, 1.49)
Cancer
No 493 109 1 1
Yes 32 10 1.60 (0.74, 3.48) 1.19 (0.54, 2.66)
Circulation problems in legs
No 358 68 1 1
Yes 167 51 1.88 (1.23, 2.86) 1.52 (0.97, 2.38)
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secondary to altered biomechanics [44], the consequences
of these alterations may be more pronounced in other re-
gions of the foot, such as the forefoot and toes.
The proportion of participants with symptomatic mid-
foot OA who reported consulting a GP in the last
12-months for foot pain (46 %) was high compared to
previous population estimates generated within North
Staffordshire for other joint pain and problems among
adults aged 50 years and over (self-reported consultation
for knee pain, 33 % in the last 12 months [45]; and self-
reported hand problems, 22 % in last 12 months [46]). A
record-based review of consultation for musculoskeletal
foot problems in the last 18 months among adults aged
50 years and over was previously estimated at 12 % [47].
The higher estimate obtained for consultation for symp-
tomatic midfoot OA seen in our study could possibly
arise as a result of concurrent pain elsewhere in the foot
contributing to consultation, inaccurate recall of the last
12 months, and consultation rates being higher in a sub-
group of self-selecting volunteers who attended a foot
research clinic and may have more severe problems.
Nearly three-quarters of participants had recently used
some form of pain medication for foot pain. Whilst the
frequent use of oral and topical medications would ap-
pear in keeping with clinical guidelines for OA in gen-
eral, one-fifth of participants had recently used herbal or
nutraceutical preparations, which is inconsistent with
current recommendations [48].
Frequent healthcare use and associated disability must
be interpreted at the level of the foot given the high pro-
portion of people with symptomatic midfoot OA who
have hindfoot/ankle pain and forefoot pain. However, this
Table 4 Associated self-reported impairment and comorbidities among adults with symptomatic midfoot OA (Continued)
Intermittent claudicationd
No 443 94 1 1
Yes 20 4 0.93 (0.30, 2.84) 0.82 (0.26, 2.56)
Non-musculoskeletal comorbiditiese
0–1 167 23 1 1
2–3 153 30 1.53 (0.84, 2.77) 1.31 (0.71, 2.41)
4+ 137 43 2.86 (1.62, 5.06) 2.23 (1.23, 4.05)
Low back pain
No 289 49 1 1
Yes 236 70 2.07 (1.36, 3.13) 2.09 (1.37, 3.19)
Hip pain
No 321 49 1 1
Yes 204 70 2.90 (1.91, 4.41) 3.08 (2.00, 4.74)
Knee pain
No 293 51 1 1
Yes 232 68 1.97 (1.30, 2.98) 2.12 (1.38, 3.25)
Hindfoot/ankle pain
No 234 27 1 1
Yes 291 92 3.54 (2.21, 5.68) 3.63 (2.25, 5.86)
Forefoot pain
No 187 18 1 1
Yes 338 101 4.00 (2.33, 6.86) 4.50 (2.59, 7.82)
Other lower limb painf
No 77 3 1 1
Yes 448 116 8.62 (2.67, 27.87) 8.53 (2.63, 27.71)
Based on complete case clinic data
OA osteoarthritis, SMOA symptomatic midfoot osteoarthritis, OR odds ratio, CI confidence interval, SF-12 Short Form-12 [13], HADS Hospital Anxiety and Depression
Scale [14]
aEstimates adjusted for age and gender
bVariable dichotomised around the median of the data distribution
cExcludes the need for glasses
dDefined as calf pain when walking at an ordinary pace on level ground (including uphill or when hurried) that disappears in 10 min or less by standing still [26]
eCount based on each of the above self-reported variables, excluding SF-12 scores (HADS scores ≥8)
fVariable includes presence of pain in hip, knee, hindfoot/ankle or forefoot
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study indicates that people with symptomatic midfoot OA
may require management and are frequently present in
primary care, though often in the context of multimorbid-
ity and not necessarily as a discrete phenotype. The over-
whelming majority (97 %) of individuals with symptomatic
midfoot OA will report pain at other lower extremity
joints and the extent of this comorbidity is greater than
expected by chance alone. Shared aetiological pathways
would carry implications for clinical care, for example, in
addressing common causes of lower extremity pain, in
biomechanically based interventions aimed at the lower
extremity as a functional unit, and in ‘collateral benefits’
to lower extremity pain of effective local treatment to one
joint. For the local management of symptomatic midfoot
OA, there is limited evidence for interventions such as
foot orthoses [49], intra-articular corticosteroid/local an-
aesthetic injections [50] and arthrodesis [51]. Better char-
acterisation of this phenotype may help to inform more
effective targeted treatments.
Strengths of this study include census sampling from
general practice registers and the use of multiple imput-
ation and weighted logistic regression to account for se-
lection bias. Although our approach adopts recognised
statistical adjustment techniques [21], these estimates
should be viewed cautiously due to non-response. Whilst
causality cannot be inferred for obesity, OA at the knee
has been shown to cumulate through adulthood with in-
creased exposure to elevated BMI [52], and reverse asso-
ciation (symptomatic midfoot OA causing weight gain)
seems less plausible. The majority of self-reported injur-
ies occurred over 10 years ago and high-heeled footwear
exposure (between 20 and 49 years old) predated the
sample age (≥50 years old), suggesting that these expo-
sures appear to predominantly occur earlier in life.
The study has some noteworthy limitations. The clinical
sample all had foot pain in the last 12 months. Therefore,
prevalence estimates represent symptomatic individuals
and all associations are relative to foot pain elsewhere.
Consequently, observed associations may underestimate
the true effect. Despite excellent intra-rater reliability for
scoring the presence of OA in a joint, inter-rater reliability
was moderate. Furthermore, we noted that the main
scorer MM was systematically more conservative com-
pared to HBM. Therefore, the reported population preva-
lence estimates may be underestimated. Also, estimates
for previous injury, previous footwear, comorbidity and
healthcare use were derived from self-report data, and lat-
erality for co-occurring joint pain was not considered. The
footwear question designed specifically for this study has
not been validated. Both footwear and previous injury may
be particularly vulnerable to recall bias, however, attempts
were made to minimise these issues. First, in the standar-
dised clinical interview all participants were probed in re-
lation to a variety of previous injury exposures over a
number of questions to promote and assist recall. Second,
previous footwear was asked of all participants in the
health survey irrespective of foot pain status. Finally, the
selected healthcare use estimates are based on small num-
bers and therefore could only be estimated imprecisely.
Conclusions
Symptomatic midfoot OA occurs commonly in the popu-
lation aged 50 years and over. Its relationship with demo-
graphic and socio-economic factors is similar to other
forms of OA but the pattern of association with potential
determinants, together with the form and function of the
midfoot, suggest a central role for mechanical load in this
phenotype. As such it may provide a useful model for
further studies of mechanical load in OA pathogenesis.
Clinical research could focus on the effectiveness of exist-
ing and emerging non-pharmacological treatments for this
phenotype.
Additional file
Additional file 1: Table S1. Foot or ankle injury location and duration
of time since injury among adults with symptomatic midfoot OA in the
right foot.
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Table 5 Frequency of selected healthcare use for foot pain
Healthcare use for foot pain Adults with symptomatic midfoot
OA (n = 119)
N Proportion
% (95 % CI)
Healthcare professional consulted in last 12 months
GP 55 46.2 (37.1, 55.3)
Physiotherapist 22 18.5 (11.4, 25.6)
Podiatrist/chiropodist 57 47.9 (39.0, 57.0)
Any of the above 86 72.3 (64.1, 80.4)
Pain medication in last month
Paracetamol 43 36.1 (27.4, 44.9)
Mild/moderate opioids 38 31.9 (23.4, 40.4)
Topical cream/gel/spray 37 31.1 (22.7, 39.5)
NSAIDs, including coxibs 33 27.7 (19.6, 35.9)
Herbal/nutraceuticals 25 21.0 (13.6, 28.4)
Any of the above 84 70.6 (62.3, 78.9)
Based on complete case clinic data
OA osteoarthritis, CI confidence interval, GP general practitioner, NSAIDs
non-steroidal anti-inflammatory drugs
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